Delayed Myelination in Infants and Young Children: Radiographic and Clinical Correlates

Magnetic resonance imaging (MRI) is the best method for assessing myelination in infants and young children. Although delayed myelination is a common neuroradiologic diagnosis, there are few or no data regarding the reliability of this diagnosis or radiographic and clinical findings in cohorts of such patients. We evaluated the cranial MRI scans of 109 patients from age 0 to 36 months, without knowledge of any patient's age or previous clinical or radiologic diagnosis. For each cranial MRI, seven neuroradiologic landmarks were evaluated and established criteria used to assess the state of myelination. We found that in 12 of 109 patients, delayed myelination was misdiagnosed, whereas the diagnosis of delayed myelination was missed in four other patients. Lack of familiarity with the myelination milestones of infancy was the most common reason for a misdiagnosis of delayed myelination. Failure to recognize delayed myelination was due to a failure to appreciate the forceps minor as a landmark. Overall, the diagnosis of delayed myelination was inaccurately applied or missed in 15% of the patients in this series. Of the 14 patients identified as having delayed myelination, 10 had other central nervous system structural abnormalities seen on MRI, most commonly cortical atrophy. Developmental delay was the most common clinical correlate of delayed myelination and was documented in 12 of the 14 patients. To increase the reliability of neuroradiologic assessments in young children, we propose that central nervous system myelin maturation be evaluated and expressed as a myelination age equivalent, analogous to the assessment of pediatric bone age using conventional radiographs. Further, prospective studies of infants and young children with delayed myelination are needed to learn the full clinical spectrum of this common neuroradiologic diagnosis. (J Child Neurol 1995;10:100-104).

[1]  R. Reynolds,et al.  Disturbed myelinogenesis and recovery in hyperphenylalaninemia in rats: An immunohistochemical study , 1992, Experimental Neurology.

[2]  P. Yakovlev,et al.  The myelogenetic cycles of regional maturation of the brain , 1967 .

[3]  J. Volpe Brain development--normal and abnormal. , 1991, Journal of perinatal medicine.

[4]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[5]  M. Tripp,et al.  Plasma carnitine concentrations in cardiomyopathy patients. , 1984, Biochemical medicine.

[6]  J. Valk,et al.  The reflection of histology in MR imaging of Pelizaeus-Merzbacher disease. , 1989, AJNR. American journal of neuroradiology.

[7]  K. Hopper,et al.  Neurologic manifestations in 18q- syndrome. , 1990, American journal of medical genetics.

[8]  V. Herzberg Human T lymphocytes require lipid as either lipoprotein or nonesterified fatty acid for in vitro activation. , 1991, Immunological investigations.

[9]  Howard E. Gendelman,et al.  Dementia Associated with the Acquired Immunodeficiency Syndrome , 1995 .

[10]  K. Feingold,et al.  Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.

[11]  E. Walter,et al.  Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. , 1991, The Journal of pediatrics.

[12]  D. Simpson Neuromuscular Complications of Human Immunodeficiency Virus Infection , 1992, Seminars in neurology.

[13]  A. Warrington,et al.  The oligodendrocyte and its many cellular processes. , 1993, Trends in cell biology.

[14]  S. Moretti,et al.  Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L‐carnitine , 1994, AIDS.

[15]  N. Habib,et al.  Syncytia formation in HIV‐1 infected cells is associated with an increase in cellular oleic acid , 1989, FEBS letters.

[16]  J. Arenas,et al.  Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy , 1993, Muscle & nerve.

[17]  T. H. Newton,et al.  MRI of normal brain maturation. , 1986, AJNR. American journal of neuroradiology.

[18]  H. Kinney,et al.  Delayed Central Nervous System Myelination in the Sudden Infant Death Syndrome , 1991, Journal of neuropathology and experimental neurology.

[19]  J. Arenas,et al.  Plasma carnitine insufficiency and effectiveness of L‐carnitine therapy in patients with mitochondril myopathy , 1993, Muscle & nerve.

[20]  R. Shuman,et al.  The neuropathology of the nonketotic and ketotic hyperglycinemias , 1978, Neurology.

[21]  K. Feingold,et al.  Role of Cytokines in Inducing Hyperlipidemia , 1992, Diabetes.

[22]  T. Stein,et al.  Protein and energy substrate metabolism in AIDS patients. , 1990, Metabolism: clinical and experimental.

[23]  B. Brody,et al.  Sequence of Central Nervous System Myelination in Human Infancy. I. An Autopsy Study of Myelination , 1987, Journal of neuropathology and experimental neurology.

[24]  R. Wiggins Myelin development and nutritional insufficiency , 1982, Brain Research Reviews.

[25]  A. Pardee,et al.  Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. , 1993, Journal of acquired immune deficiency syndromes.

[26]  V. Vullo,et al.  High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. , 1993, Immunopharmacology and immunotoxicology.

[27]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[28]  M. Dalakas,et al.  Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[29]  J. Dobbing,et al.  Quantitative growth and development of human brain , 1973, Archives of disease in childhood.

[30]  M. Cloyd,et al.  Human immunodeficiency virus (HIV-1) cytotoxicity: perturbation of the cell membrane and depression of phospholipid synthesis. , 1988, Virology.

[31]  J. Sidtis,et al.  Cerebrospinal fluid (β2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment , 1992, AIDS.

[32]  P Evrard,et al.  Formation, maturation, and disorders of white matter. , 1992, AJNR. American journal of neuroradiology.

[33]  T. Schiano,et al.  Reversal of apparent AIDS dementia complex following treatment with vitamin B12 , 1993, Journal of internal medicine.

[34]  H. Gendelman,et al.  Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease , 1992, The Journal of experimental medicine.

[35]  C R Bird,et al.  MR assessment of myelination in infants and children: usefulness of marker sites. , 1989, AJNR. American journal of neuroradiology.

[36]  S. Lipton Human immunodefciency virus‐infected macrophages, gp120, and N‐methyl‐D‐ aspartate receptor‐mediated new‐otoxicity , 1993 .

[37]  D. Norman,et al.  Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. , 1988, Radiology.

[38]  H. Kinney,et al.  Sequence of Central Nervous System Myelination in Human Infancy. II. Patterns of Myelination in Autopsied Infants , 1988, Journal of neuropathology and experimental neurology.

[39]  M. Dalakas,et al.  The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[40]  L. Svennerholm,et al.  Lipid and fatty acid composition of human cerebral myelin during development. , 1978, Advances in experimental medicine and biology.

[41]  V. Vullo,et al.  L‐carnitine deficiency in AIDS patients , 1992, AIDS.

[42]  C. McArdle,et al.  Developmental features of the neonatal brain: MR imaging. Part I. Gray-white matter differentiation and myelination. , 1987, Radiology.

[43]  K. Woods MEDICARE: A NEW HEALTH INSURANCE PROGRAMME FOR AUSTRALIA , 1984, The Lancet.

[44]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[45]  I. Duncan Abnormalities of myelination of the central nervous system associated with congenital tremor. , 1987, Journal of veterinary internal medicine.

[46]  K. Hyland,et al.  Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection , 1990, The Lancet.

[47]  J. Bogden,et al.  Micronutrient Status and Human Immunodeficiency Virus (HIV) Infection , 1990, Annals of the New York Academy of Sciences.

[48]  D. Mildvan,et al.  Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex , 1992, The Lancet.

[49]  E. Richardson,et al.  Cerebral white-matter hypoplasia. , 1977, Archives of neurology.

[50]  J. Glass,et al.  Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dememtia , 1993, Annals of neurology.

[51]  C. De Simone,et al.  Reversibility by L-carnitine of immunosuppression induced by an emulsion of soya bean oil, glycerol and egg lecithin. , 1982, Arzneimittel-Forschung.

[52]  G. Pezeshkpour,et al.  Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. , 1991, Human pathology.

[53]  S. Dimauro,et al.  Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy , 1991, The Lancet.

[54]  Paul D. Griffiths,et al.  Magnetic Resonance Imaging of the Brain and Spine , 1996 .

[55]  J. Benjamins,et al.  Model Systems for Study of Perturbations of Myelin Metabolism , 1977 .

[56]  H. E. Solberg,et al.  Carnitine levels in human serum in health and disease. , 1974, Clinica chimica acta; international journal of clinical chemistry.

[57]  L. Epstein,et al.  Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. , 1989, American journal of diseases of children.

[58]  J. Uriel,et al.  Changes in lipid composition of human peripheral blood lymphocytes infected by HIV. , 1991, AIDS research and human retroviruses.

[59]  D. Monti,et al.  Immunomodulatory properties of L-acetylcarnitine on lymphocytes from young and old humans , 1989 .

[60]  E. Hogan,et al.  Animal Models of Genetic Disorders of Myelin , 1984 .

[61]  C. H. Chen,et al.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.

[62]  M. Mintz Clinical comparison of adult and pediatric NeuroAIDS. , 1994, Advances in neuroimmunology.

[63]  K. Feingold,et al.  In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis. , 1992, Endocrinology.

[64]  W. Gahl,et al.  Zidovudine‐induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage , 1994, Annals of neurology.

[65]  H. Gendelman,et al.  Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms , 1993, Annals of neurology.